3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
88
Lung Neoplasms
53
Carcinoma, Hepatocellular
43
Breast Neoplasms
33
Small Cell Lung Carcinoma
29
Squamous Cell Carcinoma of Head and Neck
23
Cholangiocarcinoma
22
Urinary Bladder Neoplasms
21
Colorectal Neoplasms
21
Pancreatic Neoplasms
20
Ovarian Neoplasms
17
Triple Negative Breast Neoplasms
16
Biliary Tract Neoplasms
16
Neoplasm Metastasis
13
Head and Neck Neoplasms
12
Neoplasms
11
Carcinoma, Renal Cell
11
Liver Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Transitional Cell
9
Uterine Cervical Neoplasms
7
Esophageal Neoplasms
7
Carcinoma, Squamous Cell
7
Adenocarcinoma Of Esophagus
7
Recurrence
6
Prostatic Neoplasms
6
Mesothelioma, Malignant
6
Melanoma
6
Gallbladder Neoplasms
6
Fallopian Tube Neoplasms
6
Interventions
Cyclophosphamide
21
Cytarabine
15
blinatumomab
13
fludarabine
12
Azacitidine
10
venetoclax
9
fludarabine phosphate
9
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Rituximab
6
Mercaptopurine
6
Daunorubicin
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Etoposide
4
Busulfan
4
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm, Residual
×
durvalumab
×
Clear all
NCT04944173
2024-09-03
SCION
University of British Columbia
Phase 2
Withdrawn